Anti-Cardiolipin (IgM)
aCL
aCL
Chemiluminescent immunoassay on the BIO-Flash analyzer (Werfen)
Serum
Send: 0.3 mL for 1 test or 0.6 mL min for several of:
- aCL
- dsDNA
- tTG (IgA)
- MPO
- PR3
- anti-SM
- SSb
- Ro52
- Ro60
- RNP
Frozen
Anti-cardiolipin (aCL) antibodies belong to a heterogeneous family of antiphospholipid (aPL) antibodies, which are autoantibodies directed against anionic phospholipids or protein-phospholipid complexes. Assays for the determination of aCL IgG and IgM antibodies, anti-β2 glycoprotein-1 (anti- β2GP1) IgG and IgM antibodies and lupus anticoagulant antibodies are the aPL assays defined in the revised classification criteria determined by the International Committee for the diagnosis of APS in the meeting held in 2006 in Sydney, Australia. Both the aCL and anti-β2GP1 assays contain human β2 glycoprotein-1 (β2GP1) on the solid phase. β2 glycoprotein-1, also called apolipoprotein H, is a 44 kDA glycoprotein with 5 domains that is present in plasma. The fifth domain contains a cluster of positively charged amino acids which is responsible for the binding of anionic phospholipids. The mechanism by which aCL and anti-β2GP1 antiphospholipid antibodies recognize β2GP1 is unclear. Two main theories have been proposed; the first known as “dimerization theory” considers that one antibody must bind two β2GP1 molecules to obtain increased avidity, and the second “cryptic epitope theory” considers that the aCL and antiβ2GP1 antiphospholipid binding epitope is only exposed when β2GP1 binds to a negatively charged surface or negative molecules such cardiolipin. This epitope is located in domain I.
Persistently elevated levels of aPL antibodies are associated with an increased risk for vascular thrombosis and obstetrical complications. This association is known as antiphospholipid syndrome, classification proposed by Harris in 1987.
Browse tests by laboratory
Customer Service
Toll Free: 1-855-381-3212
Local: 416-813-7200